Work

Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab + rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC).

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.3_suppl.456

Authors: Stephen Lam Chan, Ahmed Omar Kaseb, Wei Shi, Laura Alexander, Xianzhang Meng, CheolHee Park, Kristin Ryan, Arndt Vogel

Institutions: Chinese University of Hong Kong, The University of Texas MD Anderson Cancer Center, Jiangsu Hengrui Medicine (China), Medizinische Hochschule Hannover

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4391095202

Cites:

Cited by: 2

Related to: 10